Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × posaconazole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 9 Myelodysplastic Syndromes 3 Mycoses 3 Hematologic Neoplasms 2 Brain Neoplasms 2 Triple Negative Breast Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neutropenia 1 Neoplasms 1 Neoplasm, Residual 1 Myelodysplastic-Myeloproliferative Diseases 1 Mucormycosis 1 Leukemia, Myeloid 1 Leukemia 1 Glioma 1 Glioblastoma 1 Genetic Predisposition to Disease 1 Candidiasis 1 Breast Neoplasms 1 Bone Marrow Failure Disorders 1 Aspergillosis 1 Anemia, Aplastic 1

Interventions

Trastuzumab 520 Paclitaxel 472 Cyclophosphamide 467 Docetaxel 411 Capecitabine 348 Letrozole 309 Fulvestrant 268 Doxorubicin 245 Tamoxifen 228 Carboplatin 224 Anastrozole 197 Radiotherapy 193 exemestane 186 Epirubicin 170 Bevacizumab 166 palbociclib 149 Lapatinib 145 Vinorelbine 143 pertuzumab 141 Gemcitabine 138 pembrolizumab 136 Surveys and Questionnaires 118 Exercise 110 Magnetic Resonance Spectroscopy 109 eribulin 103 Fluorouracil 101 Albumin-Bound Paclitaxel 100 Blood Specimen Collection 96 130-nm albumin-bound paclitaxel 90 Everolimus 87

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06802757 2026-02-25

PRISM-TNBC

Shandong Cancer Hospital and Institute

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡